Gastritis News and Research

RSS

Gastritis is not a single disease, but several different conditions that all have inflammation of the stomach lining. Gastritis can be caused by drinking too much alcohol, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen, or infection with bacteria such as Helicobacter pylori (H. pylori). Sometimes gastritis develops after major surgery, traumatic injury, burns, or severe infections. Certain diseases, such as pernicious anemia, autoimmune disorders, and chronic bile reflux, can cause gastritis as well.

Helicobacter pylori infection found to lower cognition among adults in the UK

Researchers evaluated the association between Helicobacter pylori and cognition.

9 Jun 2023

Immune cells in the duodenum may be responsible for iron absorption problems, study suggests

Approximately one to two milligrams of the trace element must be supplied daily through food and finally absorbed in the duodenum for a balanced iron metabolism.

20 Apr 2023

Antioxidant-rich phenolic compounds: A key to disease prevention, gut health, and brain homeostasis

Researchers report on the benefits of consuming dietary phenols and their relationship with the intestinal microbiome.

10 Apr 2023

Study examines the causal role of insomnia symptoms on 11,409 health related-symptoms

Researchers performed Mendelian randomization phenome-wide association study of insomnia symptoms using 11,409 outcome variables.

6 Apr 2023

What effect do nuts have on gastrointestinal health?

Researchers presented an overview of the latest research on the impact of nut intake on gastrointestinal health.

4 Apr 2023

What is the gastrointestinal impact of Long Covid?

Researchers assessed gastrointestinal outcomes associated with COVID-19.

9 Mar 2023

The efficacy of clarithromycin versus levofoxacin-based regimens for H.pylori treatment in naïve patients after the COVID-19 pandemic misuse of antibiotics

Researchers explored the eradication rates of Helicobacter pylori utilizing levofloxacin and clarithromycin-based regimens in patients with prior COVID-19 therapy.

25 Jan 2023

Should we be getting used to the idea of eating insects?

A recent Molecules journal study has reviewed the literature on edible insects as a source of bioactive compounds.

15 Jan 2023

Chemical residue from commercial dishwashers causes gut epithelial barrier damage

Residue from rinse agents is left behind on dishes after they are cleaned in professional-grade dishwashers.

1 Dec 2022

Study reveals an increase in the prevalence of digestive diseases

Data from a new pan-European study on the burden of digestive diseases, presented today at UEG Week 2022 and published in the United European Gastroenterology Journal, highlights a worrying increase in the prevalence of several digestive diseases since 2000. These include chronic liver diseases, pancreatitis, gastroesophageal reflux disease, gastritis, vascular intestinal disorders and coeliac disease in children. In addition, the incidence and mortality rates for all digestive cancers combined have increased by 26% and 17% respectively in the period 2000-2019.

10 Oct 2022

As California welcomes Ukrainian refugees, counties fall short on interpreters

After the Russian invasion, Katie Nelha and her husband couldn't safely return to their home in Mykolaiv, Ukraine, so they took their chances as refugees.

12 Jul 2022

New sensor accurately determines the human saliva pH

Chemists at the Ural Federal University have created a sensor for determining the human saliva pH. This is a fluorophore with strong and stable emission, which picks up the smallest fluctuations in the pH(tenths) in biological fluids.

16 Jun 2022

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

Exploring vitamin D and acute COVID-19 infection

Researchers assessed the presence of vitamin D deficiency in COVID-19-recovered patients

6 May 2022

Study confirms accuracy of new generation GastroPanel® test

A clinical validation study conducted at Oulu University Hospital (OUH) has confirmed the high accuracy of BIOHIT Oyj’s new generation GastroPanel® test for the diagnosis of atrophic gastritis (AG) and Helicobacter pylori (Hp) infection in patients referred for gastroscopy.

From BIOHIT HealthCare Ltd 6 May 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Study reveals new way viruses trigger autoimmunity

Autoimmune diseases such as rheumatoid arthritis and Type 1 diabetes are thought to arise when people with a genetic susceptibility to autoimmunity encounter something in the environment that triggers their immune systems to attack their own bodies.

28 Feb 2022

Faxes and snail mail: Will pandemic-era flaws unleash improved health technology?

Jamie Taylor received two letters from the Missouri Department of Social Services Family Support Division that began, "Good news," before stating that she was denied Medicaid coverage.

1 Feb 2022

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021